« Back to Record
Citation APA

Mathieu, C., Wych, J., Hendriks, E. A., Van Ryckeghem, L., Tree, T., Chmura, P., Möller, C., Casteels, K., Danne, T., Reschke, F., Šmigoc Schweiger, D., Battelino, T., Johannesen, J., Rami-Merhar, B., Pieber, T., De Block, C., Evans, M., Hilbrands, R., Bosi, E., Willemsen, R. H., Basu, S., Pulkkinen, M. A., Knip, M., Cnop, M., Nitsche, A., Schulte, A. M., Niemöller, E., Peakman, M., Wilhelm-Benartzi, C., Gillespie, D., Overbergh, L., Mander, A. P., Marcovecchio, M. L., & INNODIA, (2025). Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet, 406(10510), 1375-1388. doi:10.1016/S0140-6736(25)01674-5


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/408956

Mathieu, C., Wych, J., Hendriks, E. A., Van Ryckeghem, L., Tree, T., Chmura, P., Möller, C., Casteels, K., Danne, T., Reschke, F., Šmigoc Schweiger, D., Battelino, T., Johannesen, J., Rami-Merhar, B., Pieber, T., De Block, C., Evans, M., Hilbrands, R., Bosi, E., Willemsen, R. H., Basu, S., Pulkkinen, M. A., Knip, M., Cnop, M., Nitsche, A., Schulte, A. M., Niemöller, E., Peakman, M., Wilhelm-Benartzi, C., Gillespie, D., Overbergh, L., Mander, A. P., Marcovecchio, M. L., & INNODIA, (2025). Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet, 406(10510), 1375-1388. doi:10.1016/S0140-6736(25)01674-5